AI Article Synopsis
- Genome-wide association studies (GWAS) have significantly advanced our understanding of coronary artery disease (CAD) and are paving the way for better drug development.
- The review identifies key challenges in pinpointing causal genes and interpreting risk variants related to CAD while also showcasing new biological insights obtained from GWAS findings.
- Emphasis is placed on the role of precision medicine and "omics" data in discovering new treatment targets, ultimately enhancing cardiovascular research outcomes.
Article Abstract
The achievement of genome-wide association studies (GWAS) has rapidly progressed our understanding of the etiology of coronary artery disease (CAD). It unlocks new strategies to strengthen the stalling of CAD drug development. In this review, we highlighted the recent drawbacks, mainly pointing out those involved in identifying causal genes and interpreting the connections between disease pathology and risk variants. We also benchmark the novel insights into the biological mechanism behind the disease primarily based on outcomes of GWAS. Furthermore, we also shed light on the successful discovery of novel treatment targets by introducing various layers of "omics" data and applying systems genetics strategies. Lastly, we discuss in-depth the significance of precision medicine that is helpful to improve through GWAS analysis in cardiovascular research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpcardiol.2023.101821 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!